Related Experiment Video

Updated: Jun 2, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

The role of mirk kinase in sarcomas

Eileen Friedman1

  • 1Department of Pathology, Upstate Medical University, 750 East Adams Street, 2305 Weiskotten Hall, Syracuse, NY 13210, USA.

Sarcoma
|May 12, 2011
PubMed

Insights

Targeting the Mirk/dyrk1B kinase may offer a new treatment for osteosarcomas and rhabdomyosarcomas. Inhibiting Mirk increases damaging reactive oxygen species (ROS), leading to tumor cell death and sensitizing them to chemotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Targeting tyrosine kinases like KIT has improved gastrointestinal stromal tumor treatment.
  • Other kinases represent potential therapeutic targets for common sarcomas.

Purpose of the Study:

  • To investigate the role of Mirk/dyrk1B kinase in osteosarcomas and rhabdomyosarcomas.
  • To evaluate Mirk/dyrk1B as a potential therapeutic target for sarcoma treatment.

Main Methods:

  • Assessed Mirk/dyrk1B expression in sarcoma cell lines.
  • Depleted Mirk/dyrk1B in tumor cells and observed effects on apoptosis and reactive oxygen species (ROS) levels.
  • Examined the impact of Mirk/dyrk1B depletion on chemosensitivity.
  • Compared Mirk/dyrk1B expression and effects of depletion in normal cells versus tumor cells.

Main Results:

  • Mirk/dyrk1B kinase is highly expressed in most osteosarcomas and rhabdomyosarcomas, mediating tumor growth.
  • Mirk/dyrk1B depletion induced tumor cell apoptosis and increased damaging ROS levels.
  • Mirk/dyrk1B-depleted tumor cells showed increased sensitivity to ROS-increasing chemotherapeutic drugs.
  • Mirk expression is low in normal cells, and its depletion or knockout did not affect normal cell survival.

Conclusions:

  • Mirk/dyrk1B is a promising therapeutic target for osteosarcomas and rhabdomyosarcomas.
  • Targeting Mirk/dyrk1B may offer a sarcoma treatment strategy with minimal toxicity to normal tissues due to its low expression in healthy cells.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...